Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections

Steady-state pharmacokinetics of oral fleroxacin were studied in six males who had skin or skin structure infections and who were receiving 400 mg of fleroxacin once a day. Blood samples (n = 10) and total urine output were collected during a 24-h dosing interval. Fleroxacin concentrations in serum and urine were determined by high-performance liquid chromatography. The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively. The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively. Fleroxacin disposition in this patient population was similar to that in noninfected volunteers with normal renal function.

[1]  R. Portmann,et al.  Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans , 1987, Antimicrobial Agents and Chemotherapy.

[2]  L. Verbist Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone. , 1987, The Journal of antimicrobial chemotherapy.

[3]  G. Drusano,et al.  Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients , 1987, Antimicrobial Agents and Chemotherapy.

[4]  K. Lenz,et al.  Pharmacokinetics of ceftazidime and netilmicin in patients with sepsis. , 1987, International journal of clinical pharmacology, therapy, and toxicology.

[5]  K. Aldridge,et al.  RO23-6240, a new orally absorbed quinolone: in vitro comparison with other broad-spectrum oral antimicrobial agents and imipenem. , 1987, Diagnostic microbiology and infectious disease.

[6]  R. Wise,et al.  Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone , 1987, Antimicrobial Agents and Chemotherapy.

[7]  W. Jusko,et al.  Pharmacokinetics of aztreonam in patients with gram-negative infections , 1985, Antimicrobial Agents and Chemotherapy.

[8]  E. Swabb,et al.  Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects , 1983, Antimicrobial Agents and Chemotherapy.